Severe aplastic anemia (SAA) is a rare but serious hematologic disorder. The treatment of SAA is based on immunosuppressive therapy (IST) and allogeneic hematopoietic cell transplantation (HCT). In many centers, allogeneic HCT is recommended for patients younger than 50 years, if an HLA-identical sibling donor is available. For patients younger than 50 years who lack an HLA-identical sibling donor, IST based on cyclosporine and ATG is recommended as first-line treatment, and allogeneic HCT with an unrelated donor is recommended after failure to respond to IST. 1 In patients older than 50 years, allogeneic HCT, even with an HLA-identical sibling as donor, is generally only recommended after failure of IST.
During the last two decades, the outcome of allogeneic HCT for SAA with an unrelated donor has improved significantly. [2] [3] [4] Owing to the improved outcome of allogeneic HCT with unrelated donors, it is considered if this treatment should be given an increased role in the future treatment of children and young adults with SAA and no available HLA-identical sibling donor.
To answer the question, whether outcome of patients with SAA transplanted with an unrelated donor is approaching the outcome of patients transplanted with a related donor, we retrospectively analyzed the outcome of all patients treated with allogeneic HCT for SAA in a single institution in Denmark between 1977 and 2013. Table 1 .
In all patients (n = 96), 10-year overall survival (OS) was 74% with a median observation time of 6.5 years (0-33; Supplementary  Figure 1) .
Altogether, 24 patients died, 11 patients (46%) due to infection with or without GVHD, 3 patients (13%) due to GVHD, 3 patients (13%) due to rejection and 7 patients (29%) due to other or unknown reasons. No deaths were reported to be from secondary malignancies.
Five-year OS in patients transplanted before 31 December 2000 (n = 45) was 60%, whereas survival in patients transplanted after 31 December 2000 (n = 51) increased to 90% and the difference was highly significant (P o 0.0001). Median observation times were 15.0 years (0-33) and 5.1 years (0-13), respectively (Supplementary Figure 2) . The one-year treatment-related mortality (TRM) in patients transplanted before vs after 31 December 2000 was 37.8% vs 7.8% and the difference was highly significant (P o 0.001).
In patients transplanted before 31 December 2000, 10-year OS among patients transplanted with a related vs an unrelated donor was 63% vs 46%, respectively, and the median observation time was 18.0 and 10.0 years, respectively (data not shown). In the group of patients transplanted before vs after 31 December 2000, the cumulative incidence of aGVHD grade II-IV at day +100 was 36% vs 14%, respectively (P = 0.01), and the cumulative incidence of cGVHD (any grade) at 2 years after HCT was 29% vs 12% (P = 0.042). In the group of patients transplanted with a related donor before vs after 31 December 2000, the cumulative incidence of aGVHD grade II-IV at day +100 was 28% vs 13% (P = 0.16), and in the group of patients transplanted with an unrelated donor before vs after 31 December 2000, the cumulative incidence of aGVHD grade II-IV at day +100 was 54% vs 15% (P = 0.012).
In patients transplanted after 31 December 2000, 5-year OS was 96% after transplantation with a related donor (n = 25) and 89% after transplantation with an unrelated (n = 26) donor and the difference was not significant (P = 0.33). Median observation times were 6.5 years (0-13) and 4.1 years (0-11), respectively ( Figure 1 ).
In the group of patients transplanted after 31 December 2000 with a related vs an unrelated donor, the cumulative incidence of aGVHD grade II-IV at day 100 was 13% and 15%, respectively (P = 0.78) and the cumulative incidence of cGVHD (any grade) at 2 years after HCT was 4% and 11.5%, respectively (P = 0.11).
In a uni-and multivariable Cox regression analysis for OS as response, year of transplant had a hazard ratio of 0.94 (95% confidence interval = 0.90-0.98, P = 0.001) in the univariate analysis and a hazard ratio of 0.91 (95% confidence interval = 0.87-0.96, Po 0.001) in the multivariate analysis (age at HCT and donor type (related or unrelated donor) were covariats).
In this retrospective, population-based single-institution study, we have analyzed the outcome of 96 consecutive patients treated with allogeneic HCT for SAA from 1977 to 2013.
In the whole group, we found a 10-year OS of 73% with a follow-up time up to 33 years. The probability of long-time OS was not negatively influenced by late complications or deaths because of secondary cancers even though many patients received highdose TBI. We found a significant decrease in TRM and a significant improvement in OS among patients transplanted after 31 December 2000. In accordance with other larger studies, 2-4 the OS has improved mostly among patients transplanted with an unrelated donor. The reduction of TBI dose from 1200 to 200 cGy may have contributed, but improved HLA matching and improved standard of care may also have played an important role.
The OS in patients transplanted after 31 December was comparable to that in other centers. Interestingly, the OS among patients transplanted with a related versus an unrelated donor was similar and there were no significant differences in the pre-HCT characteristics that could explain the lack of negative impact of an unrelated donor on prognosis.
We report a low cumulative incidence of both aGVHD and cGVHD in patients transplanted after 31 December 2000 and that the incidence both aGVHD and cGVHD was significantly lower than in patients transplanted before 31 December 2000. The most significant decrease in the incidence of aGVHD was among patients transplanted with an unrelated donor. The reduced incidence of GVHD may have contributed to the improved survival in patients transplanted after 31 December 2000.
In patients transplanted after 31 December 2000, we report a similar incidence of aGVHD in patients transplanted with a related compared with an unrelated donor. We found a trend toward less cGVHD in the patients transplanted with a related donor, although the difference was not significant. Allogeneic HCT for SAA with an umbilical cord as graft source is generally not recommended if a related or an unrelated donor is available because of high risk of graft rejection, transplantation-related mortality, infectious complications and GVHD. [5] [6] [7] [8] [9] The conditioning regimen based on cyclophosphamide and ATG and the use of bone marrow as donor graft still seem to be an optimal setting for allogeneic HCT for SAA.
Our study has several limitations, apart from the inherent drawbacks of a retrospective study. The outcome of HCT is affected by a selection bias since only the fit patients are referred to HCT. This applies particularly to the patients who received IST as first-line therapy, relapsed or progressed, and were referred to HCT with an unrelated donor as second-line therapy. Furthermore, the follow-up period of patients transplanted after year 2000 is also relatively short.
In conclusion, we believe this study shows that the outcome of patients transplanted for SAA with an unrelated donor is approaching the outcome of patients transplanted with a related donor. Allogeneic HCT with unrelated donor should therefore be considered as first-line treatment for SAA in patients eligible for transplant, lacking an HLA-identical sibling donor. Immunosuppressive treatment will, in many cases, still be recommendable while search for an unrelated donor is ongoing.
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